NCT03529084WITHDRAWNanonymous

A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

Sponsor

Source record

Novartis Pharmaceuticals

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

EFG816, erlotinib or gefitinib

Indication / condition

AI-normalized

Carcinoma, Non-small Cell Lung

Intervention

Source record

EFG816, erlotinib or gefitinib

Related intelligence directories

Indication directory: Carcinoma Modality directory: small molecule Target directory: EFG816

Source & freshness

Source record

NCT ID

NCT03529084

Original source

ClinicalTrials.gov

Source last updated

Nov 22, 2019

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03529084

Title

A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

Sponsor

Novartis Pharmaceuticals

Status

WITHDRAWN

Phase

PHASE3

Condition raw

Carcinoma, Non-small Cell Lung

Condition normalized

Carcinoma, Non-small Cell Lung

Modality raw

small molecule

Modality normalized

small molecule

Target raw

EFG816, erlotinib or gefitinib

Target normalized

EFG816, erlotinib or gefitinib

Interventions

EFG816, erlotinib or gefitinib

Public preview

Source record

This is a phase III, open label, randomized controlled multi-center global study designed to evaluate the safety and efficacy of single agent nazartinib (EGF816) compared with investigator's choice (erlotinib or gefitinib) in patients with locally advanced or metastatic NSCLC who are treatment naïve and whose tumors harbor EGFR activating mutations (L858R or ex19del).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

Source & freshness

Public preview

Create an account to unlock this report

A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts